CHA Vaccine Research Institute
Develops vaccines and immunotherapeutics using proprietary adjuvant platforms.
261780 | KO
Overview
Corporate Details
- ISIN(s):
- KR7261780001
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 중원구 둔촌대로 560, 406,407호(상대원동, 벽산테크노피아), 성남시
- Website:
- http://en.chavaccine.com/
- Sector:
- Manufacturing
Description
CHA Vaccine Research Institute is a research-oriented biotechnology company focused on developing vaccines and immunotherapeutics for the prevention and treatment of infectious diseases. The company's core strategy involves leveraging proprietary adjuvant platforms, such as L-pampo and L-pampo, which are based on Toll-like receptor (TLR) ligands, to enhance vaccine efficacy. Its development pipeline includes a third-generation prophylactic vaccine and a therapeutic vaccine for Hepatitis B (HBV), a recombinant vaccine for herpes zoster (shingles), and an improved influenza vaccine. In addition to its vaccine portfolio, the institute is developing immunotherapeutic proteins like recombinant Mannose-Binding Lectin (MBL) for broad-spectrum pathogen suppression.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-11-17 00:00 |
증권발행결과(자율공시)(제4회차 CB)
|
Korean | 5.6 KB | ||
| 2023-11-15 00:00 |
주요사항보고서(전환사채권발행결정)
|
Korean | 51.1 KB | ||
| 2023-11-13 00:00 |
분기보고서 (2023.09)
|
Korean | 926.1 KB | ||
| 2023-11-09 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 26.8 KB | ||
| 2023-10-13 00:00 |
투자판단관련주요경영사항(임상시험계획변경승인)(재조합 대상포진 백신(CVI-VZV-001)의 제 1상 임상시험 계획 변경승인)
|
Korean | 16.5 KB | ||
| 2023-10-05 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 22.1 KB | ||
| 2023-10-05 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 22.4 KB | ||
| 2023-08-11 00:00 |
반기보고서 (2023.06)
|
Korean | 906.7 KB | ||
| 2023-08-09 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.3 KB | ||
| 2023-08-01 00:00 |
투자판단관련주요경영사항(임상시험계획변경승인신청)(재조합 대상포진 백신(CVI-VZV-001)의 제 1상 임상시험 계획 변경승인 신청)
|
Korean | 15.5 KB | ||
| 2023-05-12 00:00 |
분기보고서 (2023.03)
|
Korean | 909.7 KB | ||
| 2023-04-04 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.4 KB | ||
| 2023-04-04 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.5 KB | ||
| 2023-03-30 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.3 KB | ||
| 2023-03-27 00:00 |
정기주주총회결과
|
Korean | 26.2 KB |
Automate Your Workflow. Get a real-time feed of all CHA Vaccine Research Institute filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CHA Vaccine Research Institute
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CHA Vaccine Research Institute via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
